{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '2.', 'TABLE OF CONTENTS AND LISTS OF TABLES AND FIGURES', 'TABLE OF CONTENTS', 'PROTOCOL APPROVAL', '2', \"INVESTIGATOR'S AGREEMENT\", '3', '1.', 'SYNOPSIS', '4', '2.', 'TABLE OF CONTENTS AND LISTS OF TABLES AND FIGURES', '14', '3.', 'ABBREVIATIONS AND DEFINITIONS', '21', '4.', 'INTRODUCTION', '23', '4.1.', 'Primary Mitochondrial Myopathy (PMM)', '23', '4.1.1.', 'Background', '23', '4.1.2.', 'Etiology', '23', '4.1.3.', 'Pathophysiology', '24', '4.1.4.', 'Clinical Presentation', '25', '4.1.5.', 'Prevalence', '25', '4.1.6.', 'Burden of Disease', '26', '4.1.7.', 'Treatment', '26', '4.2.', 'Pharmacologic Basis for Elamipretide as a Potential Treatment for Primary', 'Mitochondrial Myopathy (PMM)', '26', '4.3.', 'Elamipretide Risk/Benefit Assessment', '27', '4.3.1.', 'Clinical Efficacy in Studies in Primary Mitochondrial Myopathy (PMM)', '27', '4.3.1.1.', 'SPIMM-201', '27', '4.3.1.2.', 'SPIMM-202', '28', '4.3.2.', 'Summary of Safety', '31', '4.3.2.1.', 'Nonclinical Study Safety Findings', '31', '4.3.2.2.', 'Clinical Trial Safety Findings', '32', '4.4.', 'Discussion of Trial Design and Control', '35', '4.5.', 'Rationale for Selection of Doses in the Trial', '35', '5.', 'TRIAL OBJECTIVES', '38', '5.1.', 'PART 1 Objectives', '38', '5.1.1.', 'Primary Objective', '38', '5.1.2.', 'Secondary Objectives', '38', '5.1.3.', 'Exploratory Objectives', '38', '5.1.4.', 'Pharmacokinetics (PK)', '39', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '14']['SPIMM-301 Version 4.0', '15 June 2018', '5.2.', 'PART 2 Objective', '39', '6.', 'INVESTIGATIONAL PLAN', '40', '6.1.', 'SPIMM-301 Overall Trial Design', '40', '6.1.1.', 'PART 1', '40', '6.1.1.1.', 'PART 1 Screening Period', '40', '6.1.1.2.', 'PART 1 Treatment Period', '41', '6.1.1.3.', 'PART 1 Follow-Up Period (for subjects not continuing into PART 2)', '41', '6.1.2.', 'PART 2', '42', '6.1.2.1.', 'PART 2 Treatment Period', '42', '6.1.2.2.', 'PART 2 Follow-Up Period', '42', '6.2.', 'Schedule of Visit Assessments', '42', '6.2.1.', 'PART 1', '42', '6.2.1.1.', 'Screening Visit/Period: Day -28 to Day -1 (minimum of 7 days)', '42', '6.2.1.2.', 'Baseline Visit (Day 1)', '43', '6.2.1.3.', 'Double-Blind Treatment Period', '45', '6.2.1.4.', 'Week 4 (Day 29 =2), Week 12 (Day 85 4), and Week 24 (Day 169+14', 'days) Visits', '45', '6.2.1.5.', 'PART 1 Post-Treatment Follow-Up Period (4 weeks [+7 days])', '46', '6.2.2.', 'PART 2', '47', '6.2.2.1.', 'PART 2 Treatment Period', '48', '6.2.2.2.', 'PART 2 Post-Treatment Follow-Up Period (4 weeks [+7 days])', '48', '6.3.', 'Description of Trial Procedures', '49', '6.3.1.', 'Medical/Surgical History and Concomitant Medications/Procedures', '49', '6.3.2.', 'Physical Examination', '49', '6.3.3.', 'Columbia Suicide Severity Rating Scale (C-SSRS)', '50', '6.3.4.', 'Vital Signs', '50', '6.3.5.', 'Electrocardiograms (ECGs)', '50', '6.3.6.', 'Clinical Laboratory Testing', '50', '6.3.7.', 'Pregnancy Tests', '50', '6.3.8.', 'Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)', '50', '6.3.9.', 'The Neuro-QoL Fatigue', '51', '6.3.10.', 'EQ-5D-5L', '51', '6.3.11.', 'Patient Global Impression (PGI) Scales', '51', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '15']\n\n###\n\n", "completion": "END"}